

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM707333

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Neos Therapeutics, Inc.		01/26/2022	Corporation:
RECEIVING PARTY DATA			
Name:	AVENUE VENTURE OPPORTUNITIES FUND II, L.P.		
Street Address:	11 West 42nd Street, 9th Floor		
Internal Address:	Attn: Todd Greenbarg		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10036		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Serial Number:	90315616	ALUMBRIA	
Serial Number:	88471408	ALUMBRIA XR-ODT	
Serial Number:	88832316	VOZENTEZ	
Serial Number:	87599332	ADZENYS ER	
Serial Number:	86847780	COTEMPLA XR-ODT	
Serial Number:	86847760	ADZENYS XR-ODT	
Serial Number:	86847757		
CORRESPONDENCE DATA			
Fax Number:	6167423999		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6167423945		
Email:	hkooy@btlaw.com		
Correspondent Name:	Barnes & Thornburg LLP		
Address Line 1:	655 West Broadway, Suite 1300		
Address Line 2:	Hillary Kooy		
Address Line 4:	San Diego, CALIFORNIA 92101		
ATTORNEY DOCKET NUMBER:	82485.12		
NAME OF SUBMITTER:	Hillary Kooy		

OP \$190.00 90315616

SIGNATURE:	/Hillary Kooy/
DATE SIGNED:	02/09/2022
Total Attachments: 7 source=03. Avenue - Aytu - IP Security Agreement Neos Tx EXECUTED (1.2022)#page1.tif source=03. Avenue - Aytu - IP Security Agreement Neos Tx EXECUTED (1.2022)#page2.tif source=03. Avenue - Aytu - IP Security Agreement Neos Tx EXECUTED (1.2022)#page3.tif source=03. Avenue - Aytu - IP Security Agreement Neos Tx EXECUTED (1.2022)#page4.tif source=03. Avenue - Aytu - IP Security Agreement Neos Tx EXECUTED (1.2022)#page5.tif source=03. Avenue - Aytu - IP Security Agreement Neos Tx EXECUTED (1.2022)#page6.tif source=03. Avenue - Aytu - IP Security Agreement Neos Tx EXECUTED (1.2022)#page7.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT**, dated as of January 26, 2022 (the "**Agreement**") between **AVENUE VENTURE OPPORTUNITIES FUND, L.P.** ("**Lender**") and **NEOS THERAPEUTICS, INC.**, a Delaware corporation ("**Grantor**"), is made with reference to the Loan and Security Agreement, dated as of January 26, 2022 (as amended from time to time, the "**Loan Agreement**"), between Lender, **AVENUE VENTURE OPPORTUNITIES FUND II, L.P.**, Grantor, and the other Borrowers party thereto. Terms defined in the Loan Agreement have the same meaning when used in this Agreement.

For good and valuable consideration, receipt of which is hereby acknowledged, Grantor hereby covenants and agrees as follows:

To secure the Obligations under the Loan Agreement, Grantor grants to Lender a security interest in all right, title, and interest of Grantor in any of the following, whether now existing or hereafter acquired or created in any and all of the following property (collectively, the "**Intellectual Property Collateral**"):

(a) copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held (collectively, the "**Copyrights**"), including the Copyrights described in **Exhibit A**;

(b) trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks (collectively, the "**Trademarks**"), including the Trademarks described in **Exhibit B**;

(c) patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same (collectively, the "**Patents**"), including the Patents described in **Exhibit C**;

(d) mask work or similar rights available for the protection of semiconductor chips or other products (collectively, the "**Mask Works**");

(e) trade secrets, and any and all intellectual property rights in computer software and computer software products;

(f) design rights;

(g) claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

The rights and remedies of Lender with respect to the security interests granted hereunder are in addition to those set forth in the Loan Agreement, and those which are now or hereafter available to Lender as a matter of law or equity; provided that such rights and remedies are subject to any applicable limitations arising under Article 9 of the Uniform Commercial Code. Each right, power and remedy of Lender provided for herein or in the Loan Agreement, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every

right, power or remedy provided for herein, and the exercise by Lender of any one or more of such rights, powers or remedies does not preclude the simultaneous or later exercise by Lender of any other rights, powers or remedies; provided that such rights, powers, and remedies are subject to any applicable limitations arising under Article 9 of the Uniform Commercial Code.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

GRANTOR:

NEOS THERAPEUTICS, INC., a Delaware corporation

By: Joshua Disbrow

Name: Joshua Disbrow

Title: Chief Executive Officer

Address for Notices:

Attn: Mark Oki, CFO
373 Inverness Parkway, Suite 206,
Englewood, CO 80112

LENDER:

AVENUE VENTURE OPPORTUNITIES FUND, L.P.

By: Avenue Venture Opportunities Partners, LLC

Its: General Partner

By: _____

Name: Sonia Gardner

Title: Authorized Signatory

Address for Notices:

Attn: Todd Greenbarg
11 West 42nd Street, 9th Floor
New York, New York 10036
Tel: (212) 878-3523

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

GRANTOR:

NEOS THERAPEUTICS, INC., a Delaware corporation

By: _____

Name: Joshua Disbrow

Title: Chief Executive Officer

Address for Notices:

Attn: Mark Oki, CFO
373 Inverness Parkway, Suite 206,
Englewood, CO 80112

LENDER:

AVENUE VENTURE OPPORTUNITIES FUND, L.P.

By: Avenue Venture Opportunities Partners, LLC

Its: General Partner

By: _____

Name: Sonia Gardner

Title: Authorized Signatory

Address for Notices:

Attn: Todd Greenbarg
11 West 42nd Street, 9th Floor
New York, New York 10036
Tel: (212) 878-3523

EXHIBIT A
COPYRIGHTS

Please Check if No Copyrights Exist

<u>Type Of Work:</u>	<u>Title:</u>	<u>International Standard Serial Number (ISSN):</u>	<u>Registration Number:</u>	<u>Filing Date:</u>	<u>Preregistered?</u>

EXHIBIT B
TRADEMARKS

Please Check if No Trademarks Exist

	<u>Mark / Title</u>	<u>U.S. Serial Number:</u>	<u>U.S. Registration Number:</u>	<u>USPTO Reference Number:</u>	<u>Filing Date or Registration Date</u>
1.	ALUMBRIA	90315616			Nov. 12, 2020
2.	ALUMBRIA XR-ODT	88471408			Jun. 13, 2019
3.	VOZENTEZ	88832316			Mar. 12, 2020
4.	ADZENYS ER	87599332	5628952		Sep. 07, 2017
5.	COTEMPLA XR-ODT	86847780	5387222		Dec. 14, 2015
6.	ADZENYS XR-ODT	86847760	5147879		Dec. 14, 2015
7.		86847757	5111115		Dec. 14, 2015

